Global Gestational Trophoblastic Disease Production, Demand and Key Producers, 2022-2028
Gestational trophoblastic disease (GTD) is a group of rare diseases in which abnormal trophoblast cells grow inside the uterus after conception. In gestational trophoblastic disease (GTD), a tumor develops inside the uterus from tissue that forms after conception (the joining of sperm and egg).
This report studies the global Gestational Trophoblastic Disease demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Gestational Trophoblastic Disease, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Gestational Trophoblastic Disease that contribute to its increasing demand across many markets.
The global Gestational Trophoblastic Disease market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).
Highlights and key features of the study
Global Gestational Trophoblastic Disease total market, 2017-2028, (USD Million)
Global Gestational Trophoblastic Disease total market by region & country, CAGR, 2017-2028, (USD Million)
U.S. VS China: Gestational Trophoblastic Disease total market, key domestic companies and share, (USD Million)
Global Gestational Trophoblastic Disease revenue by player and market share 2017-2022, (USD Million)
Global Gestational Trophoblastic Disease total market by Type, CAGR, 2017-2028, (USD Million)
Global Gestational Trophoblastic Disease total market by Application, CAGR, 2017-2028, (USD Million)
This reports profiles major players in the global Gestational Trophoblastic Disease market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol Myers Squibb, Antares Pharma, Novartis AG, Accord Healthcare Limited, Eli Lilly and Company, Sanofi, Bayer AG, Amgen and Merck KGaA, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Gestational Trophoblastic Disease market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.
Global Gestational Trophoblastic Disease Market, By Region:
1. How big is the global Gestational Trophoblastic Disease market?
2. What is the demand of the global Gestational Trophoblastic Disease market?
3. What is the year over year growth of the global Gestational Trophoblastic Disease market?
4. What is the total value of the global Gestational Trophoblastic Disease market?
5. Who are the major players in the global Gestational Trophoblastic Disease market?
6. What are the growth factors driving the market demand?
This report studies the global Gestational Trophoblastic Disease demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Gestational Trophoblastic Disease, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Gestational Trophoblastic Disease that contribute to its increasing demand across many markets.
The global Gestational Trophoblastic Disease market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).
Highlights and key features of the study
Global Gestational Trophoblastic Disease total market, 2017-2028, (USD Million)
Global Gestational Trophoblastic Disease total market by region & country, CAGR, 2017-2028, (USD Million)
U.S. VS China: Gestational Trophoblastic Disease total market, key domestic companies and share, (USD Million)
Global Gestational Trophoblastic Disease revenue by player and market share 2017-2022, (USD Million)
Global Gestational Trophoblastic Disease total market by Type, CAGR, 2017-2028, (USD Million)
Global Gestational Trophoblastic Disease total market by Application, CAGR, 2017-2028, (USD Million)
This reports profiles major players in the global Gestational Trophoblastic Disease market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol Myers Squibb, Antares Pharma, Novartis AG, Accord Healthcare Limited, Eli Lilly and Company, Sanofi, Bayer AG, Amgen and Merck KGaA, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Gestational Trophoblastic Disease market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.
Global Gestational Trophoblastic Disease Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Chemotherapy
- Surgery
- Radiation Therapy
- Others
- Hospitals
- Clinics
- Cancer Research Institutes
- Others
- Bristol Myers Squibb
- Antares Pharma
- Novartis AG
- Accord Healthcare Limited
- Eli Lilly and Company
- Sanofi
- Bayer AG
- Amgen
- Merck KGaA
- Teva Pharmaceuticals
- B.P Pharma
1. How big is the global Gestational Trophoblastic Disease market?
2. What is the demand of the global Gestational Trophoblastic Disease market?
3. What is the year over year growth of the global Gestational Trophoblastic Disease market?
4. What is the total value of the global Gestational Trophoblastic Disease market?
5. Who are the major players in the global Gestational Trophoblastic Disease market?
6. What are the growth factors driving the market demand?
'@LOT1 SUPPLY SUMMARY
1.1 Gestational Trophoblastic Disease Introduction
1.2 World Gestational Trophoblastic Disease Market Size & Forecast (2017 & 2021 & 2028)
1.3 World Gestational Trophoblastic Disease Total Market by Region
1.3.1 World Gestational Trophoblastic Disease Market Size by Region (2017-2028)
1.3.2 United States Gestational Trophoblastic Disease Market Size (2017-2028)
1.3.3 China Gestational Trophoblastic Disease Market Size (2017-2028)
1.3.4 Europe Gestational Trophoblastic Disease Market Size (2017-2028)
1.3.5 Japan Gestational Trophoblastic Disease Market Size (2017-2028)
1.3.6 South Korea Gestational Trophoblastic Disease Market Size (2017-2028)
1.3.7 ASEAN Gestational Trophoblastic Disease Market Size (2017-2028)
1.3.8 India Gestational Trophoblastic Disease Market Size (2017-2028)
1.4 Market Drivers, Restraints and Trends
1.4.1 Gestational Trophoblastic Disease Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Gestational Trophoblastic Disease Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 WORLD GESTATIONAL TROPHOBLASTIC DISEASE COMPANIES COMPETITIVE ANALYSIS
2.1 World Gestational Trophoblastic Disease Revenue by Player (2017-2022)
2.2 Industry Rank and Concentration Rate (CR)
2.2.1 Global Gestational Trophoblastic Disease Industry Rank of Major Players
2.2.2 Global Concentration Ratios (CR4) for Gestational Trophoblastic Disease in 2021
2.2.3 Global Concentration Ratios (CR8) for Gestational Trophoblastic Disease in 2021
2.3 Gestational Trophoblastic Disease Company Evaluation Quadrant
2.4 Gestational Trophoblastic Disease Market: Overall Company Footprint Analysis
2.4.1 Gestational Trophoblastic Disease Market: Region Footprint
2.4.2 Gestational Trophoblastic Disease Market: Company Product Type Footprint
2.4.3 Gestational Trophoblastic Disease Market: Company Product Application Footprint
2.5 Competitive Environment
2.5.1 Historical Structure of the Industry
2.5.2 Barriers of Market Entry
2.5.3 Factors of Competition
2.6 Mergers, Acquisitions Activity
3 UNITED STATES VS CHINA VS REST OF THE WORLD
3.1 United States VS China: Gestational Trophoblastic Disease Market Comparison
3.1.1 United States VS China: Gestational Trophoblastic Disease Market Size Comparison (2017 & 2021 & 2028)
3.1.2 United States VS China: Gestational Trophoblastic Disease Market Size Market Share Comparison (2017 & 2021 & 2028)
3.2 United States Gestational Trophoblastic Disease Major Players and Market Share, 2017-2022
3.2.1 Major Players of Gestational Trophoblastic Disease in United States, Headquarters (States, Country)
3.2.2 United States Gestational Trophoblastic Disease Revenue by Domestic Player, (2017-2022)
3.3 China Gestational Trophoblastic Disease Major Players and Market Share, 2017-2022
3.3.1 Major Players of Gestational Trophoblastic Disease in China, Headquarters (Province, Country)
3.3.2 China Gestational Trophoblastic Disease Revenue by Domestic Player, (2017-2022)
3.4 Rest of World Gestational Trophoblastic Disease Major Players and Market Share, 2017-2022
3.4.1 Major Players of Gestational Trophoblastic Disease in Rest of World, Headquarters (State, Country)
3.4.2 Rest of World Gestational Trophoblastic Disease Revenue by Domestic Player, (2017-2022)
4 MARKET ANALYSIS BY TYPE
4.1 World Gestational Trophoblastic Disease Market Size Overview by Type: 2017 VS 2021 VS 2028
4.2 Segment Introduction by Type
4.2.1 Chemotherapy
4.2.2 Surgery
4.2.3 Radiation Therapy
4.2.4 Others
4.3 Market Segment by Type
4.3.1 World Gestational Trophoblastic Disease Market Size by Type (2017-2022)
4.3.2 World Gestational Trophoblastic Disease Market Size by Type (2023-2028)
4.3.3 World Gestational Trophoblastic Disease Market Size Market Share by Type (2017-2028)
5 MARKET ANALYSIS BY APPLICATION
5.1 World Gestational Trophoblastic Disease Market Size Overview by Application: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Application
5.2.1 Hospitals
5.2.2 Clinics
5.2.3 Cancer Research Institutes
5.2.4 Others
5.2.5 Others
5.3 Market Segment by Application
5.3.1 World Gestational Trophoblastic Disease Market Size by Application (2017-2022)
5.3.2 World Gestational Trophoblastic Disease Market Size by Application (2023-2028)
5.3.3 World Gestational Trophoblastic Disease Market Size by Application (2017-2028)
6 COMPANY PROFILES
6.1 Bristol Myers Squibb
6.1.1 Bristol Myers Squibb Details
6.1.2 Bristol Myers Squibb Major Business
6.1.3 Bristol Myers Squibb Gestational Trophoblastic Disease Product and Services
6.1.4 Bristol Myers Squibb Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.1.5 Bristol Myers Squibb Recent Developments/Updates
6.1.6 Bristol Myers Squibb Competitive Strengths & Weaknesses
6.2 Antares Pharma
6.2.1 Antares Pharma Details
6.2.2 Antares Pharma Major Business
6.2.3 Antares Pharma Gestational Trophoblastic Disease Product and Services
6.2.4 Antares Pharma Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.2.5 Antares Pharma Recent Developments/Updates
6.2.6 Antares Pharma Competitive Strengths & Weaknesses
6.3 Novartis AG
6.3.1 Novartis AG Details
6.3.2 Novartis AG Major Business
6.3.3 Novartis AG Gestational Trophoblastic Disease Product and Services
6.3.4 Novartis AG Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.3.5 Novartis AG Recent Developments/Updates
6.3.6 Novartis AG Competitive Strengths & Weaknesses
6.4 Accord Healthcare Limited
6.4.1 Accord Healthcare Limited Details
6.4.2 Accord Healthcare Limited Major Business
6.4.3 Accord Healthcare Limited Gestational Trophoblastic Disease Product and Services
6.4.4 Accord Healthcare Limited Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.4.5 Accord Healthcare Limited Recent Developments/Updates
6.4.6 Accord Healthcare Limited Competitive Strengths & Weaknesses
6.5 Eli Lilly and Company
6.5.1 Eli Lilly and Company Details
6.5.2 Eli Lilly and Company Major Business
6.5.3 Eli Lilly and Company Gestational Trophoblastic Disease Product and Services
6.5.4 Eli Lilly and Company Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.5.5 Eli Lilly and Company Recent Developments/Updates
6.5.6 Eli Lilly and Company Competitive Strengths & Weaknesses
6.6 Sanofi
6.6.1 Sanofi Details
6.6.2 Sanofi Major Business
6.6.3 Sanofi Gestational Trophoblastic Disease Product and Services
6.6.4 Sanofi Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.6.5 Sanofi Recent Developments/Updates
6.6.6 Sanofi Competitive Strengths & Weaknesses
6.7 Bayer AG
6.7.1 Bayer AG Details
6.7.2 Bayer AG Major Business
6.7.3 Bayer AG Gestational Trophoblastic Disease Product and Services
6.7.4 Bayer AG Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.7.5 Bayer AG Recent Developments/Updates
6.7.6 Bayer AG Competitive Strengths & Weaknesses
6.8 Amgen
6.8.1 Amgen Details
6.8.2 Amgen Major Business
6.8.3 Amgen Gestational Trophoblastic Disease Product and Services
6.8.4 Amgen Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.8.5 Amgen Recent Developments/Updates
6.8.6 Amgen Competitive Strengths & Weaknesses
6.9 Merck KGaA
6.9.1 Merck KGaA Details
6.9.2 Merck KGaA Major Business
6.9.3 Merck KGaA Gestational Trophoblastic Disease Product and Services
6.9.4 Merck KGaA Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.9.5 Merck KGaA Recent Developments/Updates
6.9.6 Merck KGaA Competitive Strengths & Weaknesses
6.10 Teva Pharmaceuticals
6.10.1 Teva Pharmaceuticals Details
6.10.2 Teva Pharmaceuticals Major Business
6.10.3 Teva Pharmaceuticals Gestational Trophoblastic Disease Product and Services
6.10.4 Teva Pharmaceuticals Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.10.5 Teva Pharmaceuticals Recent Developments/Updates
6.10.6 Teva Pharmaceuticals Competitive Strengths & Weaknesses
6.11 B.P Pharma
6.11.1 B.P Pharma Details
6.11.2 B.P Pharma Major Business
6.11.3 B.P Pharma Gestational Trophoblastic Disease Product and Services
6.11.4 B.P Pharma Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.11.5 B.P Pharma Recent Developments/Updates
6.11.6 B.P Pharma Competitive Strengths & Weaknesses
7 RAW MATERIAL AND INDUSTRY CHAIN
7.1 Raw Material of Gestational Trophoblastic Disease and Key Manufacturers
7.2 Gestational Trophoblastic Disease Manufacturing Costs
7.3 Gestational Trophoblastic Disease Production Process
7.4 Gestational Trophoblastic Disease Industrial Chain
8 DISTRIBUTION CHANNEL ANALYSIS
8.1 Distribution Channel Breakdown for Gestational Trophoblastic Disease Shipments (%): 2017-2028
8.1.1 Direct Channel
8.1.2 Indirect Channel
8.2 Gestational Trophoblastic Disease Typical Distributors
8.3 Gestational Trophoblastic Disease Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Gestational Trophoblastic Disease Introduction
1.2 World Gestational Trophoblastic Disease Market Size & Forecast (2017 & 2021 & 2028)
1.3 World Gestational Trophoblastic Disease Total Market by Region
1.3.1 World Gestational Trophoblastic Disease Market Size by Region (2017-2028)
1.3.2 United States Gestational Trophoblastic Disease Market Size (2017-2028)
1.3.3 China Gestational Trophoblastic Disease Market Size (2017-2028)
1.3.4 Europe Gestational Trophoblastic Disease Market Size (2017-2028)
1.3.5 Japan Gestational Trophoblastic Disease Market Size (2017-2028)
1.3.6 South Korea Gestational Trophoblastic Disease Market Size (2017-2028)
1.3.7 ASEAN Gestational Trophoblastic Disease Market Size (2017-2028)
1.3.8 India Gestational Trophoblastic Disease Market Size (2017-2028)
1.4 Market Drivers, Restraints and Trends
1.4.1 Gestational Trophoblastic Disease Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Gestational Trophoblastic Disease Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 WORLD GESTATIONAL TROPHOBLASTIC DISEASE COMPANIES COMPETITIVE ANALYSIS
2.1 World Gestational Trophoblastic Disease Revenue by Player (2017-2022)
2.2 Industry Rank and Concentration Rate (CR)
2.2.1 Global Gestational Trophoblastic Disease Industry Rank of Major Players
2.2.2 Global Concentration Ratios (CR4) for Gestational Trophoblastic Disease in 2021
2.2.3 Global Concentration Ratios (CR8) for Gestational Trophoblastic Disease in 2021
2.3 Gestational Trophoblastic Disease Company Evaluation Quadrant
2.4 Gestational Trophoblastic Disease Market: Overall Company Footprint Analysis
2.4.1 Gestational Trophoblastic Disease Market: Region Footprint
2.4.2 Gestational Trophoblastic Disease Market: Company Product Type Footprint
2.4.3 Gestational Trophoblastic Disease Market: Company Product Application Footprint
2.5 Competitive Environment
2.5.1 Historical Structure of the Industry
2.5.2 Barriers of Market Entry
2.5.3 Factors of Competition
2.6 Mergers, Acquisitions Activity
3 UNITED STATES VS CHINA VS REST OF THE WORLD
3.1 United States VS China: Gestational Trophoblastic Disease Market Comparison
3.1.1 United States VS China: Gestational Trophoblastic Disease Market Size Comparison (2017 & 2021 & 2028)
3.1.2 United States VS China: Gestational Trophoblastic Disease Market Size Market Share Comparison (2017 & 2021 & 2028)
3.2 United States Gestational Trophoblastic Disease Major Players and Market Share, 2017-2022
3.2.1 Major Players of Gestational Trophoblastic Disease in United States, Headquarters (States, Country)
3.2.2 United States Gestational Trophoblastic Disease Revenue by Domestic Player, (2017-2022)
3.3 China Gestational Trophoblastic Disease Major Players and Market Share, 2017-2022
3.3.1 Major Players of Gestational Trophoblastic Disease in China, Headquarters (Province, Country)
3.3.2 China Gestational Trophoblastic Disease Revenue by Domestic Player, (2017-2022)
3.4 Rest of World Gestational Trophoblastic Disease Major Players and Market Share, 2017-2022
3.4.1 Major Players of Gestational Trophoblastic Disease in Rest of World, Headquarters (State, Country)
3.4.2 Rest of World Gestational Trophoblastic Disease Revenue by Domestic Player, (2017-2022)
4 MARKET ANALYSIS BY TYPE
4.1 World Gestational Trophoblastic Disease Market Size Overview by Type: 2017 VS 2021 VS 2028
4.2 Segment Introduction by Type
4.2.1 Chemotherapy
4.2.2 Surgery
4.2.3 Radiation Therapy
4.2.4 Others
4.3 Market Segment by Type
4.3.1 World Gestational Trophoblastic Disease Market Size by Type (2017-2022)
4.3.2 World Gestational Trophoblastic Disease Market Size by Type (2023-2028)
4.3.3 World Gestational Trophoblastic Disease Market Size Market Share by Type (2017-2028)
5 MARKET ANALYSIS BY APPLICATION
5.1 World Gestational Trophoblastic Disease Market Size Overview by Application: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Application
5.2.1 Hospitals
5.2.2 Clinics
5.2.3 Cancer Research Institutes
5.2.4 Others
5.2.5 Others
5.3 Market Segment by Application
5.3.1 World Gestational Trophoblastic Disease Market Size by Application (2017-2022)
5.3.2 World Gestational Trophoblastic Disease Market Size by Application (2023-2028)
5.3.3 World Gestational Trophoblastic Disease Market Size by Application (2017-2028)
6 COMPANY PROFILES
6.1 Bristol Myers Squibb
6.1.1 Bristol Myers Squibb Details
6.1.2 Bristol Myers Squibb Major Business
6.1.3 Bristol Myers Squibb Gestational Trophoblastic Disease Product and Services
6.1.4 Bristol Myers Squibb Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.1.5 Bristol Myers Squibb Recent Developments/Updates
6.1.6 Bristol Myers Squibb Competitive Strengths & Weaknesses
6.2 Antares Pharma
6.2.1 Antares Pharma Details
6.2.2 Antares Pharma Major Business
6.2.3 Antares Pharma Gestational Trophoblastic Disease Product and Services
6.2.4 Antares Pharma Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.2.5 Antares Pharma Recent Developments/Updates
6.2.6 Antares Pharma Competitive Strengths & Weaknesses
6.3 Novartis AG
6.3.1 Novartis AG Details
6.3.2 Novartis AG Major Business
6.3.3 Novartis AG Gestational Trophoblastic Disease Product and Services
6.3.4 Novartis AG Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.3.5 Novartis AG Recent Developments/Updates
6.3.6 Novartis AG Competitive Strengths & Weaknesses
6.4 Accord Healthcare Limited
6.4.1 Accord Healthcare Limited Details
6.4.2 Accord Healthcare Limited Major Business
6.4.3 Accord Healthcare Limited Gestational Trophoblastic Disease Product and Services
6.4.4 Accord Healthcare Limited Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.4.5 Accord Healthcare Limited Recent Developments/Updates
6.4.6 Accord Healthcare Limited Competitive Strengths & Weaknesses
6.5 Eli Lilly and Company
6.5.1 Eli Lilly and Company Details
6.5.2 Eli Lilly and Company Major Business
6.5.3 Eli Lilly and Company Gestational Trophoblastic Disease Product and Services
6.5.4 Eli Lilly and Company Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.5.5 Eli Lilly and Company Recent Developments/Updates
6.5.6 Eli Lilly and Company Competitive Strengths & Weaknesses
6.6 Sanofi
6.6.1 Sanofi Details
6.6.2 Sanofi Major Business
6.6.3 Sanofi Gestational Trophoblastic Disease Product and Services
6.6.4 Sanofi Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.6.5 Sanofi Recent Developments/Updates
6.6.6 Sanofi Competitive Strengths & Weaknesses
6.7 Bayer AG
6.7.1 Bayer AG Details
6.7.2 Bayer AG Major Business
6.7.3 Bayer AG Gestational Trophoblastic Disease Product and Services
6.7.4 Bayer AG Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.7.5 Bayer AG Recent Developments/Updates
6.7.6 Bayer AG Competitive Strengths & Weaknesses
6.8 Amgen
6.8.1 Amgen Details
6.8.2 Amgen Major Business
6.8.3 Amgen Gestational Trophoblastic Disease Product and Services
6.8.4 Amgen Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.8.5 Amgen Recent Developments/Updates
6.8.6 Amgen Competitive Strengths & Weaknesses
6.9 Merck KGaA
6.9.1 Merck KGaA Details
6.9.2 Merck KGaA Major Business
6.9.3 Merck KGaA Gestational Trophoblastic Disease Product and Services
6.9.4 Merck KGaA Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.9.5 Merck KGaA Recent Developments/Updates
6.9.6 Merck KGaA Competitive Strengths & Weaknesses
6.10 Teva Pharmaceuticals
6.10.1 Teva Pharmaceuticals Details
6.10.2 Teva Pharmaceuticals Major Business
6.10.3 Teva Pharmaceuticals Gestational Trophoblastic Disease Product and Services
6.10.4 Teva Pharmaceuticals Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.10.5 Teva Pharmaceuticals Recent Developments/Updates
6.10.6 Teva Pharmaceuticals Competitive Strengths & Weaknesses
6.11 B.P Pharma
6.11.1 B.P Pharma Details
6.11.2 B.P Pharma Major Business
6.11.3 B.P Pharma Gestational Trophoblastic Disease Product and Services
6.11.4 B.P Pharma Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022)
6.11.5 B.P Pharma Recent Developments/Updates
6.11.6 B.P Pharma Competitive Strengths & Weaknesses
7 RAW MATERIAL AND INDUSTRY CHAIN
7.1 Raw Material of Gestational Trophoblastic Disease and Key Manufacturers
7.2 Gestational Trophoblastic Disease Manufacturing Costs
7.3 Gestational Trophoblastic Disease Production Process
7.4 Gestational Trophoblastic Disease Industrial Chain
8 DISTRIBUTION CHANNEL ANALYSIS
8.1 Distribution Channel Breakdown for Gestational Trophoblastic Disease Shipments (%): 2017-2028
8.1.1 Direct Channel
8.1.2 Indirect Channel
8.2 Gestational Trophoblastic Disease Typical Distributors
8.3 Gestational Trophoblastic Disease Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Gestational Trophoblastic Disease Market Size by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World Gestational Trophoblastic Disease Market Size by Region (2017-2022) & (USD Million)
Table 3. World Gestational Trophoblastic Disease Market Size by Region (2023-2028) & (USD Million)
Table 4. World Gestational Trophoblastic Disease Market Size Market Share by Region (2017-2022)
Table 5. World Gestational Trophoblastic Disease Market Size Market Share by Region (2023-2028)
Table 6. Major Market Trends
Table 7. World Gestational Trophoblastic Disease Revenue by Player (2017-2022) & (USD Million)
Table 8. Revenue Market Share of Key Gestational Trophoblastic Disease Players in 2021
Table 9. World Gestational Trophoblastic Disease Industry Rank of Major Player, Based on Revenue in 2021
Table 10. Global Gestational Trophoblastic Disease Company Evaluation Quadrant
Table 11. Head Office of Key Gestational Trophoblastic Disease Player
Table 12. Gestational Trophoblastic Disease Market: Company Product Type Footprint
Table 13. Gestational Trophoblastic Disease Market: Company Product Application Footprint
Table 14. Gestational Trophoblastic Disease Mergers & Acquisitions Activity
Table 15. United States VS China Gestational Trophoblastic Disease Market Size Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 16. Major Player of Gestational Trophoblastic Disease in United States, Headquarters (States, Country)
Table 17. United States Gestational Trophoblastic Disease Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 18. United States Gestational Trophoblastic Disease Revenue Market Share by Domestic Player, (2017-2022)
Table 19. Major Player of Gestational Trophoblastic Disease in China, Company Headquarters (Province, Country)
Table 20. China Gestational Trophoblastic Disease Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 21. China Gestational Trophoblastic Disease Revenue Market Share by Domestic Player, (2017-2022)
Table 22. Major Player of Gestational Trophoblastic Disease in Rest of World, Company Headquarters (State, Country)
Table 23. Rest of World Gestational Trophoblastic Disease Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 24. Rest of World Gestational Trophoblastic Disease Revenue Market Share by Domestic Player, (2017-2022)
Table 25. World Gestational Trophoblastic Disease Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 26. World Gestational Trophoblastic Disease Revenue by Type (2017-2022) & (USD Million)
Table 27. World Gestational Trophoblastic Disease Revenue by Type (2023-2028) & (USD Million)
Table 28. World Gestational Trophoblastic Disease Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 29. World Gestational Trophoblastic Disease Revenue by Application (2017-2022) & (USD Million)
Table 30. World Gestational Trophoblastic Disease Revenue by Application (2023-2028) & (USD Million)
Table 31. Bristol Myers Squibb Basic Information, Area Served and Competitors
Table 32. Bristol Myers Squibb Major Business
Table 33. Bristol Myers Squibb Gestational Trophoblastic Disease Product and Services
Table 34. Bristol Myers Squibb Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 35. Bristol Myers Squibb Recent Developments/Updates
Table 36. Bristol Myers Squibb Competitive Strengths & Weaknesses
Table 37. Antares Pharma Basic Information, Area Served and Competitors
Table 38. Antares Pharma Major Business
Table 39. Antares Pharma Gestational Trophoblastic Disease Product and Services
Table 40. Antares Pharma Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 41. Antares Pharma Recent Developments/Updates
Table 42. Antares Pharma Competitive Strengths & Weaknesses
Table 43. Novartis AG Basic Information, Area Served and Competitors
Table 44. Novartis AG Major Business
Table 45. Novartis AG Gestational Trophoblastic Disease Product and Services
Table 46. Novartis AG Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 47. Novartis AG Recent Developments/Updates
Table 48. Novartis AG Competitive Strengths & Weaknesses
Table 49. Accord Healthcare Limited Basic Information, Area Served and Competitors
Table 50. Accord Healthcare Limited Major Business
Table 51. Accord Healthcare Limited Gestational Trophoblastic Disease Product and Services
Table 52. Accord Healthcare Limited Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 53. Accord Healthcare Limited Recent Developments/Updates
Table 54. Accord Healthcare Limited Competitive Strengths & Weaknesses
Table 55. Eli Lilly and Company Basic Information, Area Served and Competitors
Table 56. Eli Lilly and Company Major Business
Table 57. Eli Lilly and Company Gestational Trophoblastic Disease Product and Services
Table 58. Eli Lilly and Company Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 59. Eli Lilly and Company Recent Developments/Updates
Table 60. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 61. Sanofi Basic Information, Area Served and Competitors
Table 62. Sanofi Major Business
Table 63. Sanofi Gestational Trophoblastic Disease Product and Services
Table 64. Sanofi Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 65. Sanofi Recent Developments/Updates
Table 66. Sanofi Competitive Strengths & Weaknesses
Table 67. Bayer AG Basic Information, Area Served and Competitors
Table 68. Bayer AG Major Business
Table 69. Bayer AG Gestational Trophoblastic Disease Product and Services
Table 70. Bayer AG Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 71. Bayer AG Recent Developments/Updates
Table 72. Bayer AG Competitive Strengths & Weaknesses
Table 73. Amgen Basic Information, Area Served and Competitors
Table 74. Amgen Major Business
Table 75. Amgen Gestational Trophoblastic Disease Product and Services
Table 76. Amgen Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 77. Amgen Recent Developments/Updates
Table 78. Amgen Competitive Strengths & Weaknesses
Table 79. Merck KGaA Basic Information, Area Served and Competitors
Table 80. Merck KGaA Major Business
Table 81. Merck KGaA Gestational Trophoblastic Disease Product and Services
Table 82. Merck KGaA Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 83. Merck KGaA Recent Developments/Updates
Table 84. Merck KGaA Competitive Strengths & Weaknesses
Table 85. Teva Pharmaceuticals Basic Information, Area Served and Competitors
Table 86. Teva Pharmaceuticals Major Business
Table 87. Teva Pharmaceuticals Gestational Trophoblastic Disease Product and Services
Table 88. Teva Pharmaceuticals Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 89. Teva Pharmaceuticals Recent Developments/Updates
Table 90. B.P Pharma Basic Information, Area Served and Competitors
Table 91. B.P Pharma Major Business
Table 92. B.P Pharma Gestational Trophoblastic Disease Product and Services
Table 93. B.P Pharma Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 94. Gestational Trophoblastic Disease Raw Material
Table 95. Key Manufacturers of Gestational Trophoblastic Disease Raw Materials
Table 96. Gestational Trophoblastic Disease Typical Distributors
Table 97. Gestational Trophoblastic Disease Typical Customers
Table 1. World Gestational Trophoblastic Disease Market Size by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World Gestational Trophoblastic Disease Market Size by Region (2017-2022) & (USD Million)
Table 3. World Gestational Trophoblastic Disease Market Size by Region (2023-2028) & (USD Million)
Table 4. World Gestational Trophoblastic Disease Market Size Market Share by Region (2017-2022)
Table 5. World Gestational Trophoblastic Disease Market Size Market Share by Region (2023-2028)
Table 6. Major Market Trends
Table 7. World Gestational Trophoblastic Disease Revenue by Player (2017-2022) & (USD Million)
Table 8. Revenue Market Share of Key Gestational Trophoblastic Disease Players in 2021
Table 9. World Gestational Trophoblastic Disease Industry Rank of Major Player, Based on Revenue in 2021
Table 10. Global Gestational Trophoblastic Disease Company Evaluation Quadrant
Table 11. Head Office of Key Gestational Trophoblastic Disease Player
Table 12. Gestational Trophoblastic Disease Market: Company Product Type Footprint
Table 13. Gestational Trophoblastic Disease Market: Company Product Application Footprint
Table 14. Gestational Trophoblastic Disease Mergers & Acquisitions Activity
Table 15. United States VS China Gestational Trophoblastic Disease Market Size Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 16. Major Player of Gestational Trophoblastic Disease in United States, Headquarters (States, Country)
Table 17. United States Gestational Trophoblastic Disease Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 18. United States Gestational Trophoblastic Disease Revenue Market Share by Domestic Player, (2017-2022)
Table 19. Major Player of Gestational Trophoblastic Disease in China, Company Headquarters (Province, Country)
Table 20. China Gestational Trophoblastic Disease Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 21. China Gestational Trophoblastic Disease Revenue Market Share by Domestic Player, (2017-2022)
Table 22. Major Player of Gestational Trophoblastic Disease in Rest of World, Company Headquarters (State, Country)
Table 23. Rest of World Gestational Trophoblastic Disease Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 24. Rest of World Gestational Trophoblastic Disease Revenue Market Share by Domestic Player, (2017-2022)
Table 25. World Gestational Trophoblastic Disease Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 26. World Gestational Trophoblastic Disease Revenue by Type (2017-2022) & (USD Million)
Table 27. World Gestational Trophoblastic Disease Revenue by Type (2023-2028) & (USD Million)
Table 28. World Gestational Trophoblastic Disease Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 29. World Gestational Trophoblastic Disease Revenue by Application (2017-2022) & (USD Million)
Table 30. World Gestational Trophoblastic Disease Revenue by Application (2023-2028) & (USD Million)
Table 31. Bristol Myers Squibb Basic Information, Area Served and Competitors
Table 32. Bristol Myers Squibb Major Business
Table 33. Bristol Myers Squibb Gestational Trophoblastic Disease Product and Services
Table 34. Bristol Myers Squibb Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 35. Bristol Myers Squibb Recent Developments/Updates
Table 36. Bristol Myers Squibb Competitive Strengths & Weaknesses
Table 37. Antares Pharma Basic Information, Area Served and Competitors
Table 38. Antares Pharma Major Business
Table 39. Antares Pharma Gestational Trophoblastic Disease Product and Services
Table 40. Antares Pharma Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 41. Antares Pharma Recent Developments/Updates
Table 42. Antares Pharma Competitive Strengths & Weaknesses
Table 43. Novartis AG Basic Information, Area Served and Competitors
Table 44. Novartis AG Major Business
Table 45. Novartis AG Gestational Trophoblastic Disease Product and Services
Table 46. Novartis AG Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 47. Novartis AG Recent Developments/Updates
Table 48. Novartis AG Competitive Strengths & Weaknesses
Table 49. Accord Healthcare Limited Basic Information, Area Served and Competitors
Table 50. Accord Healthcare Limited Major Business
Table 51. Accord Healthcare Limited Gestational Trophoblastic Disease Product and Services
Table 52. Accord Healthcare Limited Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 53. Accord Healthcare Limited Recent Developments/Updates
Table 54. Accord Healthcare Limited Competitive Strengths & Weaknesses
Table 55. Eli Lilly and Company Basic Information, Area Served and Competitors
Table 56. Eli Lilly and Company Major Business
Table 57. Eli Lilly and Company Gestational Trophoblastic Disease Product and Services
Table 58. Eli Lilly and Company Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 59. Eli Lilly and Company Recent Developments/Updates
Table 60. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 61. Sanofi Basic Information, Area Served and Competitors
Table 62. Sanofi Major Business
Table 63. Sanofi Gestational Trophoblastic Disease Product and Services
Table 64. Sanofi Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 65. Sanofi Recent Developments/Updates
Table 66. Sanofi Competitive Strengths & Weaknesses
Table 67. Bayer AG Basic Information, Area Served and Competitors
Table 68. Bayer AG Major Business
Table 69. Bayer AG Gestational Trophoblastic Disease Product and Services
Table 70. Bayer AG Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 71. Bayer AG Recent Developments/Updates
Table 72. Bayer AG Competitive Strengths & Weaknesses
Table 73. Amgen Basic Information, Area Served and Competitors
Table 74. Amgen Major Business
Table 75. Amgen Gestational Trophoblastic Disease Product and Services
Table 76. Amgen Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 77. Amgen Recent Developments/Updates
Table 78. Amgen Competitive Strengths & Weaknesses
Table 79. Merck KGaA Basic Information, Area Served and Competitors
Table 80. Merck KGaA Major Business
Table 81. Merck KGaA Gestational Trophoblastic Disease Product and Services
Table 82. Merck KGaA Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 83. Merck KGaA Recent Developments/Updates
Table 84. Merck KGaA Competitive Strengths & Weaknesses
Table 85. Teva Pharmaceuticals Basic Information, Area Served and Competitors
Table 86. Teva Pharmaceuticals Major Business
Table 87. Teva Pharmaceuticals Gestational Trophoblastic Disease Product and Services
Table 88. Teva Pharmaceuticals Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 89. Teva Pharmaceuticals Recent Developments/Updates
Table 90. B.P Pharma Basic Information, Area Served and Competitors
Table 91. B.P Pharma Major Business
Table 92. B.P Pharma Gestational Trophoblastic Disease Product and Services
Table 93. B.P Pharma Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 94. Gestational Trophoblastic Disease Raw Material
Table 95. Key Manufacturers of Gestational Trophoblastic Disease Raw Materials
Table 96. Gestational Trophoblastic Disease Typical Distributors
Table 97. Gestational Trophoblastic Disease Typical Customers
LIST OF FIGURES
Figure 1. Gestational Trophoblastic Disease Picture
Figure 2. World Gestational Trophoblastic Disease Total Market Size: 2017 & 2021 & 2028, (USD Million)
Figure 3. World Gestational Trophoblastic Disease Total Market Size (2017-2028) & (USD Million)
Figure 4. World Gestational Trophoblastic Disease Market Size Market Share by Region (2017-2028)
Figure 5. United States Gestational Trophoblastic Disease Market Size (2017-2028) & (USD Million)
Figure 6. China Gestational Trophoblastic Disease Market Size (2017-2028) & (USD Million)
Figure 7. Europe Gestational Trophoblastic Disease Market Size (2017-2028) & (USD Million)
Figure 8. Japan Gestational Trophoblastic Disease Market Size (2017-2028) & (USD Million)
Figure 9. South Korea Gestational Trophoblastic Disease Market Size (2017-2028) & (USD Million)
Figure 10. ASEAN Gestational Trophoblastic Disease Market Size (2017-2028) & (USD Million)
Figure 11. India Gestational Trophoblastic Disease Market Size (2017-2028) & (USD Million)
Figure 12. Gestational Trophoblastic Disease Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. Producer Shipments of Gestational Trophoblastic Disease by Player Revenue ($MM) and Market Share (%): 2021
Figure 15. Global Four-firm Concentration Ratios (CR4) for Gestational Trophoblastic Disease Markets in 2021
Figure 16. Global Four-firm Concentration Ratios (CR8) for Gestational Trophoblastic Disease Markets in 2021
Figure 17. United States VS China: Gestational Trophoblastic Disease Market Size Market Share Comparison (2017 & 2021 & 2028)
Figure 18. World Gestational Trophoblastic Disease Market Size by Type, (USD Million), 2017 & 2021 & 2028
Figure 19. World Gestational Trophoblastic Disease Market Size Market Share by Type in 2021
Figure 20. Chemotherapy
Figure 21. Surgery
Figure 22. Radiation Therapy
Figure 23. Others
Figure 24. World Gestational Trophoblastic Disease Market Size Market Share by Type (2017-2028)
Figure 25. World Gestational Trophoblastic Disease Market Size by Application, (USD Million), 2017 & 2021 & 2028
Figure 26. World Gestational Trophoblastic Disease Market Size Market Share by Application in 2021
Figure 27. Hospitals
Figure 28. Clinics
Figure 29. Cancer Research Institutes
Figure 30. Others
Figure 31. World Gestational Trophoblastic Disease Market Size Market Share by Application (2017-2028)
Figure 32. Manufacturing Cost Structure Analysis of Gestational Trophoblastic Disease in 2021
Figure 33. Manufacturing Process Analysis of Gestational Trophoblastic Disease
Figure 34. Gestational Trophoblastic Disease Industrial Chain
Figure 35. Distribution Channel Breakdown for Gestational Trophoblastic Disease Shipments (%): 2017-2028
Figure 36. Direct Channel Pros & Cons
Figure 37. Indirect Channel Pros & Cons
Figure 38. Methodology
Figure 39. Research Process and Data Source
Figure 1. Gestational Trophoblastic Disease Picture
Figure 2. World Gestational Trophoblastic Disease Total Market Size: 2017 & 2021 & 2028, (USD Million)
Figure 3. World Gestational Trophoblastic Disease Total Market Size (2017-2028) & (USD Million)
Figure 4. World Gestational Trophoblastic Disease Market Size Market Share by Region (2017-2028)
Figure 5. United States Gestational Trophoblastic Disease Market Size (2017-2028) & (USD Million)
Figure 6. China Gestational Trophoblastic Disease Market Size (2017-2028) & (USD Million)
Figure 7. Europe Gestational Trophoblastic Disease Market Size (2017-2028) & (USD Million)
Figure 8. Japan Gestational Trophoblastic Disease Market Size (2017-2028) & (USD Million)
Figure 9. South Korea Gestational Trophoblastic Disease Market Size (2017-2028) & (USD Million)
Figure 10. ASEAN Gestational Trophoblastic Disease Market Size (2017-2028) & (USD Million)
Figure 11. India Gestational Trophoblastic Disease Market Size (2017-2028) & (USD Million)
Figure 12. Gestational Trophoblastic Disease Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. Producer Shipments of Gestational Trophoblastic Disease by Player Revenue ($MM) and Market Share (%): 2021
Figure 15. Global Four-firm Concentration Ratios (CR4) for Gestational Trophoblastic Disease Markets in 2021
Figure 16. Global Four-firm Concentration Ratios (CR8) for Gestational Trophoblastic Disease Markets in 2021
Figure 17. United States VS China: Gestational Trophoblastic Disease Market Size Market Share Comparison (2017 & 2021 & 2028)
Figure 18. World Gestational Trophoblastic Disease Market Size by Type, (USD Million), 2017 & 2021 & 2028
Figure 19. World Gestational Trophoblastic Disease Market Size Market Share by Type in 2021
Figure 20. Chemotherapy
Figure 21. Surgery
Figure 22. Radiation Therapy
Figure 23. Others
Figure 24. World Gestational Trophoblastic Disease Market Size Market Share by Type (2017-2028)
Figure 25. World Gestational Trophoblastic Disease Market Size by Application, (USD Million), 2017 & 2021 & 2028
Figure 26. World Gestational Trophoblastic Disease Market Size Market Share by Application in 2021
Figure 27. Hospitals
Figure 28. Clinics
Figure 29. Cancer Research Institutes
Figure 30. Others
Figure 31. World Gestational Trophoblastic Disease Market Size Market Share by Application (2017-2028)
Figure 32. Manufacturing Cost Structure Analysis of Gestational Trophoblastic Disease in 2021
Figure 33. Manufacturing Process Analysis of Gestational Trophoblastic Disease
Figure 34. Gestational Trophoblastic Disease Industrial Chain
Figure 35. Distribution Channel Breakdown for Gestational Trophoblastic Disease Shipments (%): 2017-2028
Figure 36. Direct Channel Pros & Cons
Figure 37. Indirect Channel Pros & Cons
Figure 38. Methodology
Figure 39. Research Process and Data Source
